Abbott Laboratories (ABT) expanded its presence in cancer screening with the launch of SimpleScreen CRC in the US. The test ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Abbott Laboratories (ABT) have seen a small negative price reaction in response to a larger deal for its smaller diagnostic peer Exact Sciences Corporation (EXAS), taking place at a revenue ...

The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...

Abbott Laboratories said Monday that it has received US Food and Drug Administration approval for technology that provides updates directly to patients through its CardioMEMS HF System.

Japan-based Shimadzu Corporation has started the development and validation of a mass spectrometry (MS) solution for core ...

The CardioMEMS HF System, which has been shown to reduce heart failure hospitalizations2,3 and mortality risk4,5, measures pulmonary artery pressure through an implanted sensor in the pulmonary artery ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...

Follow Abbott Laboratories as investors assess medical devices and diagnostics, the current catalyst, execution risks and the company evidence that may shape its next market move.